Author | Gary M. Strauss, MD, MPHMedical Director of the Lung Cancer ProgramTufts Medical CenterProfessor of MedicineTufts University School of MedicineBoston

Articles

Adjuvant vs Neoadjuvant Chemotherapy in Resectable NSCLC: Is That the Real Question?

May 15, 2009

ByGary M. Strauss, MD, MPHMedical Director of the Lung Cancer ProgramTufts Medical CenterProfessor of MedicineTufts University School of MedicineBoston

Besse and Le Chevalier provide us with an excellent and comprehensive review of available literature summarizing the current state of the art relating to both adjuvant and neoadjuvant (or induction) chemotherapy in resectable non–small-cell lung cancer (NSCLC).[1] They review the efficacy of adjuvant and neoadjuvant treatment in randomized clinical trials (RCTs) that employ cisplatin-based chemotherapy in stages I, II, and IIIA NSCLC, as well as meta-analyses of these RCTs.